|
131 |
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy Enthalten in npj Systems biology and applications Bd. 11, 11.6.2025, Nr. 1, date:12.2025: 1-9
|
|
|
132 |
Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding Enthalten in Scientific reports Bd. 7, 14.11.2017, Nr. 1, date:12.2017: 1-11
|
|
|
133 |
Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies Enthalten in Medical oncology Bd. 42, 17.11.2024, Nr. 1, date:1.2025: 1-7
|
|
|
134 |
Recent advances and challenges of bispecific antibodies in solid tumors Enthalten in Experimental hematology & oncology Bd. 10, 18.12.2021, Nr. 1, date:12.2021: 1-14
|
|
|
135 |
Recent advances of bispecific antibodies in solid tumors Enthalten in Journal of hematology & oncology Bd. 10, 20.9.2017, Nr. 1, date:12.2017: 1-16
|
|
|
136 |
Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines Enthalten in Biological procedures online Bd. 23, 1.7.2021, Nr. 1, date:12.2021: 1-13
|
|
|
137 |
Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis Enthalten in Cancer cell international Bd. 23, 5.9.2023, Nr. 1, date:12.2023: 1-14
|
|
|
138 |
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation Enthalten in Blood cancer journal Bd. 12, 16.8.2022, Nr. 8, date:8.2022: 1-10
|
|
|
139 |
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation Enthalten in Leukemia Bd. 32, 31.1.2018, Nr. 5, date:5.2018: 1239-1243
|
|
|
140 |
State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors Enthalten in Biochemistry (Moscow) Bd. 88, 22.9.2023, Nr. 9, date:9.2023: 1215-1231
|
|